Replies to post #32155 on Anavex Life Sciences Corp (AVXL)

[wildcard235]

Hi Scott, good question, I think.

I am mentally exhausted and I cannot evaluate that well right now. I will leave your question open in my browser while I rest to help me remember to reply later.

[ThesT]

improved in 10 out of 12 pts. = 83% NOT 83% improvement

[e024355]

Here's my assessment of the P300 data from 7/22 compared to 11/7.
7/22
Baseline P300 = ~4.9
Day 36 = ~6.75 (reached ~92% of healthy control peak)
Healthy = ~7.35
11/7
Baseline P300 = 5.99 (much higher base than 7/22)
Day 36 = 7.09 (reached 96.3% of healthy control peak)
Healthy = 7.36

I would put more weight on how close the patient reached the healthy patient versus how much improvement occurred over baseline. Somewhat apples to oranges.

[ThesT]

Wow. A weight has been lifted. POTENTIALLY 8Xs higher than Donepezil and still UNOPTIMIZED. Boom : )

[wildcard235]

Okay, Scott, I have rested and tried to study your question about comparing P300 between July and November. The bottom line is that I am not sure how they compare.

It appears that that the 38% from July and 80% from November are the same metric, of P300 amplitude from baseline, but it simply does not make sense to me. The 38% improvement (which is wonderful) appears to be for the first 12 patients at the end of Part A. The 80% improvement appears to be for all 32 patients at the end of Part A.

The 32 patients includes the first 12 patients. I cannot fathom how a result of 38% with 12 people jumped to 80% when adding 20 people. I am missing something important, I think.